Explorative study of pharmacokinetics and pharmacodynamics after change in basal insulin infusion rate.

نویسندگان

  • Charlotte A Ihlo
  • Torsten Lauritzen
  • Jeppe Sturis
  • Ole Skyggebjerg
  • Jens S Christiansen
  • Torben Laursen
چکیده

BACKGROUND The use of insulin pumps is rapidly increasing and new, technologically more advanced pumps are continuously being developed. It is of interest to assess the clinical relevance of the many technical features of these pumps, e.g., the effect on pharmacokinetics and pharmacodynamics with change in infusion rate. METHOD The aim of this study was to explore the sequence of pharmacokinetic and pharmacodynamic changes after dose doubling of the basal insulin infusion rate with subcutaneous bolus insulin injections once an hour, continuous subcutaneous insulin infusion, and continuous intravenous insulin infusion. Ten type 1 diabetes mellitus patients were included. The insulin doses were calculated based on the habitual insulin doses. The study was designed as an open-labeled, single-center, randomized, crossover exploratory trial. RESULTS Dose doubling of the basal insulin infusion rate with the three different administration protocols did not result in any clinically relevant differences in the time courses of the pharmacokinetic and pharmacodynamic parameters. With all three administration protocols, we observed a time interval of more than 6 hours before a new steady state of insulin was achieved. CONCLUSIONS Our results indicate that frequent changes in basal subcutaneous insulin infusion rates are not of significant clinical relevance on a 24-hour basis. Regarding technological features of subcutaneous insulin pumps, no discernable advantages of increasing pump stroke frequency were found. This indicates that pump stroke frequency sophistication might not be of clinical relevance in pumps used for basal subcutaneous insulin infusion.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy

OBJECTIVE Pharmacological profiles of biphasic insulin aspart 30/70 (BIAsp 30) once daily (OD), twice daily (b.i.d.), and three times daily (t.i.d.) were compared with other insulin regimens in two crossover glucose clamp studies of insulin-treated type 2 diabetic patients. RESEARCH DESIGNS AND METHODS Study 1 consisted of BIAsp 30 OD, b.i.d., and t.i.d. versus biphasic human insulin 30/70 (BHI...

متن کامل

Comparing Effects of Continuous Insulin Infusion with or without Subcutaneous Glargine Insulin on Glycemic Control in Diabetic Patients Undergoing Coronary Artery Bypass Graft (CABG)

OBJECTIVE: Hyperglycemia is associated with increased morbidity and mortality in diabetic patients following coronary artery bypass grafting. Tight glycemic control in perioperative period can reduce these events. The goal of this study was to determine whether combination of continuous infusion and subcutaneous glargine as a basal insulin could improve glycemic control. MATERIAL AND METHODS:...

متن کامل

Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1Week of Daily Administration at Bedtime in Type 2 Diabetes A randomized cross-over study

RESULTS—The glucose infusion rate area under the curve0–32 h was greater for glargine than for detemir and NPH (1,538 6 688, 1,081 6 785, and 1,170 6 703 mg/kg, respectively, P , 0.05). Glargine suppressed endogenous glucose production more than detemir (P , 0.05) and similarly to NPH (P = 0.16). Glucagon, C-peptide, free fatty acids, and b-hydroxy-butyrate were more suppressed with glargine th...

متن کامل

Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects

OBJECTIVE To compare the pharmacokinetics and pharmacodynamics of NPH, glargine, and detemir insulins in type 2 diabetic subjects. RESEARCH DESIGN AND METHODS This study used a single-blind, three-way, cross-over design. A total of 18 type 2 diabetic subjects underwent a euglycemic clamp for 32 h after a subcutaneous injection of 0.4 units/kg at 2200 h of either NPH, glargine, or detemir afte...

متن کامل

Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects A randomized cross-over study

RESULTS—The glucose infusion rate area under the curve0–32 h was greater for glargine than for detemir and NPH (1,538 6 688; 1,081 6 785; and 1,170 6 703 mg/kg, respectively; P , 0.05). Glargine suppressed endogenous glucose production more than detemir (P , 0.05) and similarly to NPH (P = 0.16). Glucagon, C-peptide, free fatty acids, and b-hydroxy-butyrate were more suppressed with glargine th...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Journal of diabetes science and technology

دوره 5 1  شماره 

صفحات  -

تاریخ انتشار 2011